资料来源：东莞证券研究所，iFinD 二、周度新股上市情况走势 从周度新股上市规模来看，上周（6 月 30 日-7 月 4 日，下同）较上上 周（6 月 23 日-6 月 27 日，下同）相比，首发募资金额多 4.40 亿元。 证券研究报告 2025 年 7 月 7 日 星期一 【新股发行跟踪（20250707）】 一、上周新股表现情况 上周（6 月 30 日-7 月 4 日）共有 1 只新股上市，上市首日涨跌幅均值 为 286.36%。其中，有 1 只新股上市首日涨幅超 100%，为信通电子。上周 无新股首日破发。 表 2：周度新股上市概况 | 期间 | | 新股上市数（主 | 首发募资 | 首日破 | 首日涨超 | 首日涨跌幅范围 | 首日涨跌幅 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 板/双创） | （亿元） | 发率 | 100%数量 | | 均值 | | 6-30 至 | 7-4 | 1 (1/0) | 6.40 | 0% | 1 | (286.36%，286.36%) | 286.36% | | 6-23 至 | 6-27 ...

智通财经APP获悉，美国对各国90天豁免期本周结束，市场持续关注美国关税谈判。港股三大指数今早 走低，恒科指午后实现翻红。截止收盘，恒生指数跌0.12%或28.23点，报23887.83点，全日成交额为 1937.9亿港元；恒生国企指数跌0.01%，报8608.54点；恒生科技指数涨0.25%，报5229.56点。 华西证券指出，现阶段恒生指数市盈率上升较快，有需要消化的空间。今年上半年累计涨幅偏大和机构 较为拥挤的港股资产未来容易出现进一步的回调，未来一段时间仍不建议无分化追高。港股市场中估值 偏低、基本面较好且贸易问题冲击较小的局部低位资产存在随着波动回调而带来的低吸的结构性机会。 蓝筹股表现 金沙中国(01928)领涨蓝筹。截至收盘，涨3.85%，报18.32港元，成交额6.43亿港元，贡献恒指2.58点。 澳门6月博彩收入同比增长19%至211亿澳门元，超出市场预期。大摩预期澳门7月博彩收入将达204亿澳 门元，同比增长10%，而今年全年博彩收入则达2380亿澳门元，同比增长5%。 其他蓝筹股方面，华润置地(01109)涨3.45%，报28.5港元，贡献恒指4.78点；理想汽车-W(02015 )涨 ...

[Table_Main] 行业研究|信息技术|半导体与半导体生产设备 证券研究报告 半导体与半导体生产设 2025 年 07 月 07 日 [Table_Title] 三星即将进入 1c 量产阶段，国产 GPU 公司沐曦集 成准备科创板上市 ——行业周报 [Table_Summary] 报告要点： 本周（2025.6.30-2025.7.6）市场回顾 1）海外 AI 芯片指数本周上涨 1.3%，本周海外芯片指数涨幅相对较 小，MPS 涨幅约 3%，台积电和博通涨幅超过 2%，英伟达上涨 1%。 Marvell 和 AMD 股价出现下滑。2）国内 AI 芯片指数本周下跌 2.8%。 本周国内 A 股芯片指数大部分成分股股价均出现下滑，寒武纪和恒玄 科技跌幅超过 6%，兆易创新接近 6%，仅有澜起科技出现小幅上涨， 涨幅 1.8%。3）英伟达映射指数本周上涨 9.3%，景旺电子涨幅超过 20%，工业富联、胜宏科技和沪电股份涨幅超过 10%，而长芯博创、 兆龙互连、麦格米特、英维克和太辰光出现小幅下滑。4）服务器 ODM 指数本周下跌 0.7%，成分股表现分化较大，鸿海精密、Wiwynn 和技 嘉下滑约 2%，Qu ...

Summary of Key Points Core Viewpoint - The Fuzhou Changle District Market Supervision Administration has released the results of food safety supervision and sampling inspections, indicating that the majority of food products tested are compliant with safety standards, although some agricultural products showed non-compliance [2]. Group 1: Inspection Results - A total of 69 batches of food from 13 categories, including edible oils, meat products, and pastries, were sampled, and all were found to be compliant [2]. - In the circulation phase, 392 batches of pre-packaged foods from 27 categories, such as beverages and vegetable products, were tested, with all passing the safety standards [2]. - For agricultural products, 120 batches were sampled across 5 subcategories, with 7 batches failing to meet safety standards [2]. Group 2: Non-compliant Products - Specific non-compliant products included mangoes and mulberries, with detected pesticide residues exceeding the allowable limits [3]. - The mango sample showed a residue level of 0.0822 mg/kg, exceeding the standard of ≤0.05 mg/kg [3]. - The mulberry sample had a residue level of 0.0609 mg/kg, also above the permissible limit [3].

Group 1 - The Brazilian chemical industry is experiencing its worst performance in over 30 years, with an operating rate of 62% in Q1 2025, down from 65% in Q1 2024, and a year-on-year production decline of 3.8% [1] - Despite increased import tariffs on various chemical products in October 2024, the industry continues to struggle, with high import levels persisting [1] - The import penetration rate for chemical products decreased from 53% in 2024 to 43% in Q1 2025, indicating some positive effects of trade protectionism [1][2] Group 2 - The chemical trade deficit reached $49.82 billion in the 12 months ending March 2025, surpassing the previous peak of $48.68 billion [2] - The CEO of Abiquim highlighted that Brazilian chemical producers are heavily reliant on imports, making them price takers in the global market, and facing high costs from energy and taxes [2] - The proposed Presiq stimulus plan aims to address structural issues in the industry, potentially increasing operating rates to 95% and generating significant GDP growth and job creation [2] Group 3 - The production costs in Brazil are significantly higher than in North America or the Middle East, which hampers competitiveness [3] - Braskem, the largest petrochemical producer in Latin America, is planning to gradually shift to ethane feedstock, but this requires substantial investment and stable natural gas supply [3]

7月7日周一，A股三大指数、港股恒生指数集体低开，但仍有多个板块表现强势。 港股稳定币概念股走强，胜利证券一度涨超10%，国泰君安国际一度涨超5%，多点数智涨近2%，中国 光大控股涨超1%。 消息面上，香港《稳定币条例》8月生效，香港特区政府财经事务及库务局局长许正宇7日表示，金管局 目前就落实条例指引咨询市场，该指引本月内公布，具体内容将涉及反洗钱及其他相关要求。 许正宇亦表明批出的稳定币牌照数目会是个位数，盼于条例生效后能够收到申请，目标今年内可发出牌 照。至于有金融机构取得牌照后，是否能够发行与人民币挂钩的稳定币，他说若牵涉其他司法权区的货 币，则要与相关机构讨论。 另外，A股还有多个板块开盘表现强势： 房地产板块异动拉升，渝开发（000514）涨停，海泰发展（600082）涨逾9%，特发服务（300917）、 我爱我家（000560）、新城控股（601155）等涨幅居前。 电力板块走强，华银电力（600744）三连板，韶能股份（000601）二连板，深南电A（000037）、西昌 电力（600505）、华电辽能（600396）、乐山电力（600644）等大涨。 中期看预计市场震荡中枢将不断抬升，短期指 ...

2025 年 07 月 07 日 晨会纪要 研究所： 证券分析师： 余春生 S0350513090001 yucs@ghzq.com.cn [Table_Title] 晨会纪要 ——2025 年第 113 期 观点精粹: 最新报告摘要 2025 年 6 月重卡销量同比显著增长，看好全年重卡内需景气度--行业动态研究 股市行情上涨，后续转债如何选择？--固定收益点评 全球领先玩具制造商，印尼新厂于年中投产--德林国际/文娱用品(01126/213605) 点评报告（港股美股） 医药行业深度报告：数说日本医疗的现代化历程，质量、效率和成本的特有平衡--产业 PPT 报告（无评级） 黄金价格波动的底层逻辑--宏观专题研究 谷歌与 CFS 签订 200MW 核聚变供电协议，产业长期发展趋势已立--事件点评 湖北省人形机器人产业投资母基金设立，步科发布第四代无框力矩电机及中空驱动器--行业周报 工信部召开光伏企业座谈会，海风政策催化不断落地--行业周报 红利资产从共识到分化的再审视--资产配置报告 光刻机行业深度报告（一）：核心部件篇，曙光已现--行业 PPT 报告 人形机器人灵巧手深度报告：灵巧手赛道蓝海可期，各类新 ...

7月7日，可申购主板上市的华电新能（600930.SH），该公司系中国华电风力发电、太阳能发电为主的 新能源业务最终整合的唯一平台。 | 打新早知道 | | | 南财快讯 | | --- | --- | --- | --- | | 今日申购 | | | | | 600930.SH 华电新能 | | | | | 机构报价(元/股) 发行价(元/股) | | 市值(亿元) | 所属行业 | | 3.18 3.35 | | 1145.00 | 电力、热力生产和 | | | | | 供应V | | 发行市盈率 | 行业市盈率 | 可比公司 | 可比公司动态市盈率 | | 15.56 | 17.84 | 龙原电力 | 14.81 | | | | 三峡能源 | 20.09 | | | | 节能风电 | 24.03 | | 业绩情况 | | | | | 400.0 | | | 100% | | 350.0 | | | 80% | | 300.0 | | | | | 250.0 | | | 60% | | 200.0 | | | | | 150.0 | | | 40% | | 100.0 | | | | | 50.0 | | ...

Company Overview - Chongqing Leishuo Power Engineering Co., Ltd. has been established with a registered capital of 40 million RMB [1] - The legal representative of the company is Wu Wenjie, and it is wholly owned by Chongqing Tengyong Enterprise Management Co., Ltd. [1] Business Scope - The company’s business scope includes installation, maintenance, and testing of power facilities, as well as power supply and generation services [1] - Additional services include hydraulic power generation, electrical installation services, construction engineering, and various technical services related to power generation and renewable energy [1] Industry Classification - The company operates within the electricity, heat, gas, and water production and supply industry, specifically focusing on electricity production [1] - The registered address is located in Shapingba District, Chongqing, indicating its operational base within a significant urban area [1]

Core Viewpoint - The rapid development of the global innovative drug industry has led to a significant opportunity for the CDMO (Contract Development and Manufacturing Organization) sector, with Shanghai Haoyuan Pharmaceutical Co., Ltd. positioning itself as a leader in the ADC (Antibody-Drug Conjugate) niche [1][2]. Group 1: Company Strategy and Market Position - Haoyuan Pharmaceutical has identified ADC as a key area for growth, establishing core competencies and positioning itself in the first tier of CDMO providers in this field [1][2]. - The company has successfully undertaken over 110 ADC projects in 2024, with 12 small molecule products related to ADC having completed FDA filings [2]. - The company reported a revenue of 2.254 billion yuan in 2024, a year-on-year increase of 20.62%, and a net profit of 202 million yuan, up 58.17% year-on-year [2]. Group 2: Technological Advancements - ADC technology, which combines antibodies, linkers, and cytotoxic drugs, allows for targeted cancer treatment, minimizing damage to normal tissues [2]. - Haoyuan Pharmaceutical has developed proprietary technologies in ADC, having been a pioneer in this field since its establishment in 2006 [3]. - The company has collaborated with AI pharmaceutical firms to enhance drug development processes, establishing an AI Drug Exploration Joint Laboratory with East China Normal University [3]. Group 3: International Expansion - The company is actively expanding its international market presence, having serviced numerous ADC "outbound" orders, with nine overseas licensing transactions reported in the first half of the year [4]. - Haoyuan Pharmaceutical has established a CDMO base in Chongqing, which is the largest of its kind in Southwest China, and has passed EU quality audits to facilitate international market expansion [4][5]. - The company has set up business warehousing centers in the US, Europe, and India, serving over 13,000 pharmaceutical companies and research institutions globally [5]. Group 4: Future Prospects - Haoyuan Pharmaceutical is not only focusing on ADC but is also exploring emerging fields such as PDC (Peptide-Drug Conjugates), RDC (Radioisotope-Drug Conjugates), and ApDC (Aptamer-Drug Conjugates) [5]. - The company aims to create a full-chain service model that integrates technology research, industrialization, and global service, thereby establishing competitive barriers [5].